Advanced search
Publication Cover
Immunopharmacology and Immunotoxicology Volume 43, 2021 - Issue 3
Submit an article Journal homepage
486
Views
6
CrossRef citations to date
0
Altmetric
Original Articles

Presence of anti-TIF-1γ, anti-Ro52, anti-SSA/Ro60 and anti-Su/Ago2 antibodies in breast cancer: a cross-sectional study

Mónica Vázquez-Del Mercadoa Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, CUCS, Universidad de Guadalajara, Guadalajara, Jalisco, México;b Hospital Civil de Guadalajara “Juan I. Menchaca”, Servicio de Reumatología, PNPC, CONACyT, Guadalajara, Jalisco, México;c UDG-CA-703, Inmunología y Reumatología, CUCS, Universidad de Guadalajara, Guadalajara, Jalisco, MéxicoCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-3823-4676
ORCID Icon,
Erika Aurora Martínez-Garcíaa Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, CUCS, Universidad de Guadalajara, Guadalajara, Jalisco, México;c UDG-CA-703, Inmunología y Reumatología, CUCS, Universidad de Guadalajara, Guadalajara, Jalisco, México;d Departamento de Fisiología, CUCS, Universidad de Guadalajara, Guadalajara, Jalisco, MéxicoORCID Iconhttps://orcid.org/0000-0001-6486-1086
ORCID Icon,
Adrián Daneri-Navarrod Departamento de Fisiología, CUCS, Universidad de Guadalajara, Guadalajara, Jalisco, México;e Laboratorio de Inmunología, Departamento de Fisiología, CUCS, Universidad de Guadalajara, Guadalajara, Jalisco, MéxicoORCID Iconhttps://orcid.org/0000-0002-8206-749X
ORCID Icon,
Eduardo Gómez-Bañuelosa Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, CUCS, Universidad de Guadalajara, Guadalajara, Jalisco, México;c UDG-CA-703, Inmunología y Reumatología, CUCS, Universidad de Guadalajara, Guadalajara, Jalisco, México;d Departamento de Fisiología, CUCS, Universidad de Guadalajara, Guadalajara, Jalisco, MéxicoORCID Iconhttps://orcid.org/0000-0001-9730-1851
ORCID Icon,
Beatriz Teresita Martín-Márqueza Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, CUCS, Universidad de Guadalajara, Guadalajara, Jalisco, México;c UDG-CA-703, Inmunología y Reumatología, CUCS, Universidad de Guadalajara, Guadalajara, Jalisco, MéxicoORCID Iconhttps://orcid.org/0000-0002-6756-4316
ORCID Icon,
Oscar Pizano-Martíneza Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, CUCS, Universidad de Guadalajara, Guadalajara, Jalisco, México;c UDG-CA-703, Inmunología y Reumatología, CUCS, Universidad de Guadalajara, Guadalajara, Jalisco, México;f Departamento de Clínicas Médicas. CUCS, Universidad de Guadalajara, Guadalajara, Jalisco, MéxicoORCID Iconhttps://orcid.org/0000-0003-3635-7071
ORCID Icon,
Eduardo A. Wilson-Manríqueza Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, CUCS, Universidad de Guadalajara, Guadalajara, Jalisco, MéxicoORCID Iconhttps://orcid.org/0000-0001-7036-9936
ORCID Icon,
Esther Guadalupe Corona-Sáncheza Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, CUCS, Universidad de Guadalajara, Guadalajara, Jalisco, México;c UDG-CA-703, Inmunología y Reumatología, CUCS, Universidad de Guadalajara, Guadalajara, Jalisco, México;d Departamento de Fisiología, CUCS, Universidad de Guadalajara, Guadalajara, Jalisco, MéxicoORCID Iconhttps://orcid.org/0000-0002-6540-2444
ORCID Icon,
Efrain Chavarria-Avilaa Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, CUCS, Universidad de Guadalajara, Guadalajara, Jalisco, México;g Departamento de Disciplinas Filosóficas, Metodológicas e Instrumentales. CUCS, Universidad de Guadalajara, Guadalajara, Jalisco, MéxicoORCID Iconhttps://orcid.org/0000-0001-7588-3870
ORCID Icon,
Flavio Sandoval-Garcíaa Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, CUCS, Universidad de Guadalajara, Guadalajara, Jalisco, México;f Departamento de Clínicas Médicas. CUCS, Universidad de Guadalajara, Guadalajara, Jalisco, MéxicoORCID Iconhttps://orcid.org/0000-0001-9251-4209
ORCID Icon &
Minoru Satohh Department of Clinical Nursing, School of Health Sciences, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, JapanORCID Iconhttps://orcid.org/0000-0001-8769-5105
ORCID Icon show all
Pages 328-333 | Received 28 Sep 2020, Accepted 19 Mar 2021, Published online: 20 Apr 2021
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Abstract

Objectives

The presence of myositis-specific antibodies (MSA), was recently reported in healthy individuals, cancer patients without myopathy and paraneoplastic rheumatic syndromes. We sought to analyze the frequency of MSA, myositis-associated antibodies (MAA) and autoantibodies related to systemic autoimmune rheumatic diseases (SARD) in breast cancer patients.

Methods

One hundred fifty-two breast cancer patients were enrolled in a cross-sectional study. Clinical information was collected, and autoantibodies tested by immunoprecipitation of an 35S-methionine-labeled K562 cell extract, enzyme-linked immunosorbent assay (ELISA) and Western blot when indicated. All statistical tests were performed using the software statistical package for the social science (SPSS) ver. 19.0 (IBM Inc., NYSE, USA).

Results

Autoantibodies associated with SARD: anti-52 kD ribonucleoprotein/tripartite motif-containing 21 (anti-Ro52/TRIM21) was found in 5.9% (9/152), anti-Sjögren syndrome-related antigen A/60 kD ribonucleoprotein antibody (anti-SSA/Ro60) in 3.9% (6/152) and anti-Su antigen/Argonaute 2 antibody (anti-Su/Ago2) in 2.6% (4/152). Meanwhile, anti-transcription intermediary factor-1γ (anti-TIF-1γ, p155/140) antibody was positive in 2 cases and anti-polymyositis/scleroderma antibody was detected in one case. As a whole, 14.47% (22/152) of breast cancer patients showed autoantibodies associated with SARD. These specific autoantibodies were not associated with the presence of rheumatic diseases except one rheumatoid arthritis patient positive for anti-Ro52/TRIM21.

Conclusions

Autoantibodies to TIF-1γ were found in two patients with breast cancer without dermatomyositis (DM). More common specificities were autoantibodies anti-SSA/Ro60, anti-Ro52/TRIM21 and anti-Su/Ago2. More studies are needed in order to establish the biological meaning of the presence of SARD-associated autoantibodies in breast cancer.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
Purchase options * Save for later

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,339.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.